EpiPen maker Mylan made a $463m agreement for the worldwide rights for a commercial product.<br />BI reports the July deal wasn't formally announced to the public and investors via a news release.<br />Nor was it discussed as part of the company's second quarter earnings on August 8th.<br />Wells Fargo analyst David Maris first spotted the deal--and wasn't happy with the Mylan's conduct.<br />We believe that investors should know more about the details of this deal, especially given its size. <br />
